CureVac Manufacturing GmbH, a wholly owned subsidiary of CureVac SE, is a biopharmaceutical company producing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on innovative ...
CureVac SE is a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on prophylactic vaccines, innovative cancer immunotherapies and ...
CureVac SE is a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on prophylactic vaccines, innovative cancer immunotherapies and ...
CureVac SE is a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on prophylactic vaccines, innovative cancer immunotherapies and ...
CureVac SE is a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on prophylactic vaccines, innovative cancer immunotherapies and ...
University: Postdoctoral Researcher (f/m/d) growing Freigeist Research Group „Pathways to Language“ The growing Freigeist Research Group Pathways to Language, led by Dr. Marlen Fröhlich and funded by the ...
University: PhD Researcher (m/f/d; 65%) in Theoretical or Experimental Pragmatics / Cognitive Science The following position is available at the Department of Linguistics of the Faculty of Humanities ...
University: Post-Doctoral Researcher (m/f/d) in Theoretical or Experimental Pragmatics / Cognitive Science The following position is available at the Department of Linguistics of the Faculty of Humanities beginning ...
Company Description Bosch Sensortec GmbH develops and markets key technologies in consumer electronics - micro-electro-mechanical sensors (MEMS), solutions and systems for smartphone applications, tablets, video game consoles, wearables, ...
Company Description Die Bosch Sensortec GmbH mit Sitz in Reutlingen ist eine hundertprozentige Tochtergesellschaft der Robert Bosch GmbH. Zum innovativen Produktportfolio gehören mikromechanische Sensoren, intelligente Sensoren mit Mikroc...
Tübingen AI Center Bewerbungsfrist: 01.04.2025 Technology Transfer Project Coordinator at the Tübingen AI Center (m/f/d, E13 TV-L, 100%, permanent) We're Hiring! The ...
This position is an on-premise job at our Tuebingen office. Your mission We are looking for an image annotation specialist, who is passionate about cutting-edge machine ...
LEAD Graduate School & Research Network and Hector Research Institute of Education Sciences and Psychology Bewerbungsfrist: 02.03.2025 Understanding and optimizing education: The at the University of ...
Hector Research Institute of Education: Postdoctoral Research Fellow (m/f/d) on Research Methods 11.02.2025 Postdoctoral Research Fellow on Research Methods (m/f/d, E 13 TV-L, limited) ...
Faculty of Law, Chair for Law and Artificial Intelligence The Chair for Law and Artificial Intelligence at the University of Tübingen conducts research on legal issues related to ...
Faculty of Law, Chair for Law and Artificial Intelligence The Chair for Law and Artificial Intelligence at the University of Tübingen conducts research on legal issues related to ...
Faculty of Law, Chair for Law and Artificial Intelligence The Chair for Law and Artificial Intelligence at the University of Tübingen conducts research on legal issues related to ...
Faculty of Humanities, Department of Linguistics Bewerbungsfrist: 15.03.2025 The following position is available in the Department of Linguistics of the Faculty of Humanities beginning June 2nd, ...
CureVac SE is a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on prophylactic vaccines, innovative cancer immunotherapies and ...
CureVac SE is a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on prophylactic vaccines, innovative cancer immunotherapies and ...
